Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Related Citations for PubMed (Select 23106420)

1.

Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.

Jiang H, Zeng J, Li W, Bifano M, Gu H, Titsch C, Easter J, Burrell R, Kandoussi H, Aubry AF, Arnold ME.

Anal Chem. 2012 Nov 20;84(22):10031-7. doi: 10.1021/ac3024558. Epub 2012 Nov 6.

PMID:
23106420
2.

Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.

Gu H, Wang J, Aubry AF, Jiang H, Zeng J, Easter J, Wang JS, Dockens R, Bifano M, Burrell R, Arnold ME.

Anal Chem. 2012 Jun 5;84(11):4844-50. doi: 10.1021/ac300442v. Epub 2012 May 10.

PMID:
22540405
4.
6.

The use of isotopes in the determination of absolute bioavailability of drugs in humans.

Lappin G, Rowland M, Garner RC.

Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):419-27. Review.

PMID:
16863443
7.

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC.

Clin Pharmacol Ther. 2006 Sep;80(3):203-15.

PMID:
16952487
8.

Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.

Gao L, Li J, Kasserra C, Song Q, Arjomand A, Hesk D, Chowdhury SK.

Anal Chem. 2011 Jul 15;83(14):5607-16. doi: 10.1021/ac2006284. Epub 2011 Jun 20.

PMID:
21627104
9.

Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.

Denton CL, Minthorn E, Carson SW, Young GC, Richards-Peterson LE, Botbyl J, Han C, Morrison RA, Blackman SC, Ouellet D.

J Clin Pharmacol. 2013 Sep;53(9):955-61. doi: 10.1002/jcph.127. Epub 2013 Jul 12.

PMID:
23846776
11.

Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

Boulton DW, Kasichayanula S, Keung CF, Arnold ME, Christopher LJ, Xu XS, Lacreta F.

Br J Clin Pharmacol. 2013 Mar;75(3):763-8. doi: 10.1111/j.1365-2125.2012.04391.x.

12.

Stable-isotope methodology for the bioavailability study of phenytoin during multiple-dosing regimens.

Kasuya Y, Mamada K, Baba S, Matsukura M.

J Pharm Sci. 1985 May;74(5):503-7.

PMID:
4020625
13.
14.
15.

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C.

Eur J Pharm Sci. 2010 May 12;40(2):125-31. doi: 10.1016/j.ejps.2010.03.009. Epub 2010 Mar 20.

PMID:
20307657
17.

Sensitivity-based analytical approaches to support human absolute bioavailability studies.

Xu XS, Jiang H, Christopher LJ, Shen JX, Zeng J, Arnold ME.

Bioanalysis. 2014 Feb;6(4):497-504. doi: 10.4155/bio.13.318.

PMID:
24568352
18.

Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.

Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Brian Houston J, Oosterhuis B, Bjerrum OJ, Grynkiewicz G, Alder J, Rowland M, Garner C.

Eur J Pharm Sci. 2011 Jun 14;43(3):141-50. doi: 10.1016/j.ejps.2011.04.009. Epub 2011 Apr 20.

PMID:
21540108
19.
20.

Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.

Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D.

J Clin Pharmacol. 2009 Dec;49(12):1408-16. doi: 10.1177/0091270009343698. Epub 2009 Sep 23.

PMID:
19776293
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk